Abstract
Pancreatic cancer (PC) is becoming a major cause of cancer death and is difficult to treat due to poor detection and late-stage diagnosis. However, various approaches have been implemented for the detection of PC at an early stage. Apart from this several chemotherapeutic drugs are suggested for patients diagnosed with PC but their applications are restricted due to systemic toxicity due to long-term usage. Nanotechnology-based therapeutic approaches have gained significant importance in both early-stage detection and targeted drug delivery in PC therapy. The nanoparticles assist in the sustained and targeted release of a drug regimen to cancer/tumor-specific sites rather than affecting healthy cells, leading to negligible or no toxicity. In this chapter, we have highlighted the significant role of various PC-specific receptors, the mechanism of nanocarrier accumulation in carcinogenic cells, biomarkers in PC diagnosis, and the role of nanocarriers in theranostic applications in the PC microenvironment.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Ansari D, Gustafsson A, Andersson R (2015) Update on the management of pancreatic cancer: surgery is not enough. World J Gastroenterol 21(11):3157–3165. https://doi.org/10.3748/wjg.v21.i11.3157
Bachem MG, Schünemann M, Ramadani M, Siech M, Beger H, Buck A, Zhou S, Schmid-Kotsas A, Adler G (2005) Pancreatic carcinoma cells induce fibrosis by stimulating proliferation and matrix synthesis of stellate cells. Gastroenterology 128(4):907–921. https://doi.org/10.1053/j.gastro.2004.12.036
Bader AG (2012) miR-34–a microRNA replacement therapy is headed to the clinic. Front Genet 3. https://doi.org/10.3389/fgene.2012.00120
Barkat HA, Barkat MA, Taleuzzaman M, Das SS, Rizwanullah M, Hadi HA (2021) Receptor-based combinatorial Nanomedicines: a new Hope for cancer management. In: Kumar S, Rizvi MA, Verma S (eds) Handbook of research on advancements in cancer therapeutics (pp. 339–355). IGI Global. https://doi.org/10.4018/978-1-7998-6530-8.ch011
Barkat HA, Das SS, Barkat MA, Beg S, Hadi HA (2020) Selective targeting of cancer signaling pathways with nanomedicines: challenges and progress. Future Oncol 16(35):2959–2979. https://doi.org/10.2217/fon-2020-0198
Bazak R, Houri M, Achy SE, Hussein W, Refaat T (2014) Passive targeting of nanoparticles to cancer: a comprehensive review of the literature. Molecular and Clinical Oncology 2(6):904–908. https://doi.org/10.3892/mco.2014.356
Bharadwaj P, Das SS, Beg S, Rahman M (2021) Formulation and biological stability of nanomedicines in cancer treatment. In: Beg S, Choudhry H, Ahmad FJ, Rahman M, Souto EB (eds) Nanoformulation strategies for cancer treatment-micro and Nano Technologies. Elsevier, pp 277–289. https://doi.org/10.1016/C2019-0-01815-8
Bisht S, Feldmann G, Soni S, Ravi R, Karikar C, Maitra A, Maitra A (2007) Polymeric nanoparticle-encapsulated curcumin (“nanocurcumin”): a novel strategy for human cancer therapy. J Nanobiotechnol 5(1). https://doi.org/10.1186/1477-3155-5-3
Bramhall SR, Schulz J, Nemunaitis J, Brown PD, Baillet M, Buckels JAC (2002) A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer. Br J Cancer 87(2):161–167. https://doi.org/10.1038/sj.bjc.6600446
Burris HA, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD, von Hoff DD (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15(6):2403–2413. https://doi.org/10.1200/jco.1997.15.6.2403
Cabral H, Murakami M, Hojo H, Terada Y, Kano MR, Chung UI, Nishiyama N, Kataoka K (2013) Targeted therapy of spontaneous murine pancreatic tumors by polymeric micelles prolongs survival and prevents peritoneal metastasis. Proc Natl Acad Sci 110(28):11397–11402. https://doi.org/10.1073/pnas.1301348110
Cai L, Michelakos T, Ferrone CR, Zhang L, Deshpande V, Shen Q, DeLeo A, Yamada T, Zhang G, Ferrone S, Wang X (2017) Expression status of folate receptor alpha is a predictor of survival in pancreatic ductal adenocarcinoma. Oncotarget 8(23):37646–37656. https://doi.org/10.18632/oncotarget.16841
Camp ER, Wang C, Little EC, Watson PM, Pirollo KF, Rait A, Cole DJ, Chang EH, Watson DK (2013) Transferrin receptor targeting nanomedicine delivering wild-type p53 gene sensitizes pancreatic cancer to gemcitabine therapy. Cancer Gene Ther 20(4):222–228. https://doi.org/10.1038/cgt.2013.9
Caputo D, Papi M, Coppola R, Palchetti S, Digiacomo L, Caracciolo G, Pozzi D (2017) A protein corona-enabled blood test for early cancer detection. Nanoscale 9(1):349–354. https://doi.org/10.1039/c6nr05609a
Caracciolo G, Safavi-Sohi R, Malekzadeh R, Poustchi H, Vasighi M, Zenezini Chiozzi R, Capriotti AL, Laganà A, Hajipour M, di Domenico M, di Carlo A, Caputo D, Aghaverdi H, Papi M, Palmieri V, Santoni A, Palchetti S, Digiacomo L, Pozzi D et al (2019) Disease-specific protein corona sensor arrays may have disease detection capacity. Nanoscale Horizons 4(5):1063–1076. https://doi.org/10.1039/c9nh00097f
Chandran SP, Natarajan SB, Chandraseharan S, Mohd Shahimi MSB (2017) Nano drug delivery strategy of 5-fluorouracil for the treatment of colorectal cancer. Journal of Cancer Research and Practice 4(2):45–48. https://doi.org/10.1016/j.jcrpr.2017.02.002
Cheng CJ, Bahal R, Babar IA, Pincus Z, Barrera F, Liu C, Svoronos A, Braddock DT, Glazer PM, Engelman DM, Saltzman WM, Slack FJ (2014) MicroRNA silencing for cancer therapy targeted to the tumour microenvironment. Nature 518(7537):107–110. https://doi.org/10.1038/nature13905
Cleary SP, Gryfe R, Guindi M, Greig P, Smith L, Mackenzie R, Strasberg S, Hanna S, Taylor B, Langer B, Gallinger S (2004) Prognostic factors in resected pancreatic adenocarcinoma: analysis of actual 5-year survivors1 1No competing interests declared. J Am Coll Surg 198(5):722–731. https://doi.org/10.1016/j.jamcollsurg.2004.01.008
Colapicchioni V, Tilio M, Digiacomo L, Gambini V, Palchetti S, Marchini C, Pozzi D, Occhipinti S, Amici A, Caracciolo G (2016) Personalized liposome–protein corona in the blood of breast, gastric and pancreatic cancer patients. Int J Biochem Cell Biol 75:180–187. https://doi.org/10.1016/j.biocel.2015.09.002
Cunningham D, Chau I, Stocken DD, Valle JW, Smith D, Steward W, Harper PG, Dunn J, Tudur-Smith C, West J, Falk S, Crellin A, Adab F, Thompson J, Leonard P, Ostrowski J, Eatock M, Scheithauer W, Herrmann R, Neoptolemos JP (2009) Phase III randomized comparison of gemcitabine versus gemcitabine plus Capecitabine in patients with advanced pancreatic cancer. J Clin Oncol 27(33):5513–5518. https://doi.org/10.1200/jco.2009.24.2446
Dai JT, Zhang Y, Li HC, Deng YH, Elzatahry AA, Alghamdi A, Fu DL, Jiang YJ, Zhao DY (2017) Enhancement of gemcitabine against pancreatic cancer by loading in mesoporous silica vesicles. Chin Chem Lett 28(3):531–536. https://doi.org/10.1016/j.cclet.2016.11.008
Danhier F, Feron O, Préat V (2010) To exploit the tumor microenvironment: passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. J Control Release 148(2):135–146. https://doi.org/10.1016/j.jconrel.2010.08.027
Das SS, Alkahtani S, Bharadwaj P, Ansari MT, ALKahtani MD, Pang Z, Hasnain MS, Nayak AK, Aminabhavi TM (2020b) Molecular insights and novel approaches for targeting tumor metastasis. Int J Pharm 585:119556. https://doi.org/10.1016/j.ijpharm.2020.119556
Das SS, Bharadwaj P, Bilal M, Barani M, Rahdar A, Taboada P, Bungau S, Kyzas GZ (2020c) Stimuli-responsive polymeric Nanocarriers for drug delivery, imaging, and Theragnosis. Polymers 12(6):1397. https://doi.org/10.3390/polym12061397
Das SS, Hussain A, Verma PRP, Imam SS, Altamimi MA, Alshehri S, Singh SK (2020d) Recent advances in liposomal drug delivery system of quercetin for cancer targeting: a mechanistic approach. Curr Drug Deliv 17(10):845–860. https://doi.org/10.2174/1567201817666200415112657
Das SS, Verma PRP, Kar S, Singh SK (2020a) Quercetin-loaded Nanomedicine as oncotherapy. In: Rahman M, Beg S, Kumar V, Ahmad FJ (eds) Nanomedicine for bioactives: healthcare applications, 1st edn. Springer, Singapore, pp 155–183. https://doi.org/10.1007/978-981-15-1664-1_5
Diasio RB, Lu Z (1994) Dihydropyrimidine dehydrogenase activity and fluorouracil chemotherapy. J Clin Oncol 12(11):2239–2242. https://doi.org/10.1200/jco.1994.12.11.2239
Douglas TA, Tamburro D, Fredolini C, Espina BH, Lepene BS, Ilag L, Espina V, Petricoin EF, Liotta LA, Luchini A (2011) The use of hydrogel microparticles to sequester and concentrate bacterial antigens in a urine test for Lyme disease. Biomaterials 32(4):1157–1166. https://doi.org/10.1016/j.biomaterials.2010.10.004
El-Zahaby SA, Elnaggar YS, Abdallah OY (2019) Reviewing two decades of nanomedicine implementations in targeted treatment and diagnosis of pancreatic cancer: An emphasis on state of art. J Control Release 293:21–35. https://doi.org/10.1016/j.jconrel.2018.11.013
Erkan M, Hausmann S, Michalski CW, Fingerle AA, Dobritz M, Kleeff J, Friess H (2012) The role of stroma in pancreatic cancer: diagnostic and therapeutic implications. Nat Rev Gastroenterol Hepatol 9(8):454–467. https://doi.org/10.1038/nrgastro.2012.115
EUR-Lex–32011H0696–EN–EUR-Lex (n.d.). Eur-Lex.europa.eu. Retrieved December 7, 2021, from http://data.europa.eu/eli/reco/2011/696/oj
Freag MS, Elnaggar YS, Abdelmonsif DA, Abdallah OY (2016) Layer-by-layer-coated lyotropic liquid crystalline nanoparticles for active tumor targeting of rapamycin. Nanomedicine 11(22):2975–2996. https://doi.org/10.2217/nnm-2016-0236
Fredolini C, Meani F, Alex Reeder K, Rucker S, Patanarut A, Botterell PJ, Bishop B, Longo C, Espina V, Petricoin EF, Liotta LA, Luchini A (2008) Concentration and preservation of very low abundance biomarkers in urine, such as human growth hormone (hGH), by Cibacron blue F3G-A loaded hydrogel particles. Nano Res 1(6):502–518. https://doi.org/10.1007/s12274-008-8054-z
Fredolini C, Meani F, Luchini A, Zhou W, Russo P, Ross M, Patanarut A, Tamburro D, Gambara G, Ornstein D, Odicino F, Ragnoli M, Ravaggi A, Novelli F, Collura D, D’Urso L, Muto G, Belluco C, Pecorelli S et al (2010) Investigation of the ovarian and prostate cancer Peptidome for candidate early detection markers using a novel nanoparticle biomarker capture technology. AAPS J 12(4):504–518. https://doi.org/10.1208/s12248-010-9211-3
Goossens N, Nakagawa S, Sun X, Hoshida Y (2015) Cancer biomarker discovery and validation. Transl Cancer Res 4(3):256. https://doi.org/10.3978/j.issn.2218-676X.2015.06.04
Hajipour MJ, Laurent S, Aghaie A, Rezaee F, Mahmoudi M (2014) Personalized protein coronas: a “key” factor at the nanobiointerface. Biomater Sci 2(9):1210. https://doi.org/10.1039/c4bm00131a
Hajipour MJ, Raheb J, Akhavan O, Arjmand S, Mashinchian O, Rahman M, Abdolahad M, Serpooshan V, Laurent S, Mahmoudi M (2015) Personalized disease-specific protein corona influences the therapeutic impact of graphene oxide. Nanoscale 7(19):8978–8994. https://doi.org/10.1039/c5nr00520e
Halford S, Yip D, Karapetis C, Strickland A, Steger A, Khawaja H, Harper P (2001) A phase II study evaluating the tolerability and efficacy of CAELYX (liposomal doxorubicin, Doxil) in the treatment of unresectable pancreatic carcinoma. Ann Oncol 12(10):1399–1402. https://doi.org/10.1023/a:1012522120294
Harshita, Barkat MA, Das SS, Pottoo FH, Beg S, Rahman Z (2020) Lipid-based nanosystem as intelligent carriers for versatile drug delivery applications. Curr Pharm Des 26(11):1167–1180. https://doi.org/10.2174/1381612826666200206094529
Hartshorn CM, Russell LM, Grodzinski P (2019) National Cancer Institute Alliance for nanotechnology in cancer–catalyzing research and translation toward novel cancer diagnostics and therapeutics. WIREs Nanomedicine and Nanobiotechnology 11(6). https://doi.org/10.1002/wnan.1570
Hoogstins CES, Boogerd LSF, Sibinga Mulder BG, Mieog JSD, Swijnenburg RJ, van de Velde CJH, Farina Sarasqueta A, Bonsing BA, Framery B, Pèlegrin A, Gutowski M, Cailler F, Burggraaf J, Vahrmeijer AL (2018) Image-guided surgery in patients with pancreatic cancer: first results of a clinical trial using SGM-101, a novel carcinoembryonic antigen-targeting, near-infrared fluorescent agent. Ann Surg Oncol 25(11):3350–3357. https://doi.org/10.1245/s10434-018-6655-7
Hu Q, Jiang Q, Jin X, Shen J, Wang K, Li Y, Xu F, Tang G, Li Z (2013) Cationic microRNA-delivering nanovectors with bifunctional peptides for efficient treatment of PANC-1 xenograft model. Biomaterials 34(9):2265–2276. https://doi.org/10.1016/j.biomaterials.2012.12.016
Hu CMJ, Kaushal S, Cao HST, Aryal S, Sartor M, Esener S, Bouvet M, Zhang L (2010) Half-antibody functionalized lipid−polymer hybrid nanoparticles for targeted drug delivery to carcinoembryonic antigen presenting pancreatic cancer cells. Mol Pharm 7(3):914–920. https://doi.org/10.1021/mp900316a
Huo Q, Colon J, Cordero A, Bogdanovic J, Baker CH, Goodison S, Pensky MY (2011) A facile nanoparticle immunoassay for cancer biomarker discovery. J Nanobiotechnol 9(1):20. https://doi.org/10.1186/1477-3155-9-20
Huo Q, Litherland SA, Sullivan S, Hallquist H, Decker DA, Rivera-Ramirez I (2012) Developing a nanoparticle test for prostate cancer scoring. J Transl Med 10(1). https://doi.org/10.1186/1479-5876-10-44
Janssen HL, Reesink HW, Lawitz EJ, Zeuzem S, Rodriguez-Torres M, Patel K, van der Meer AJ, Patick AK, Chen A, Zhou Y, Persson R, King BD, Kauppinen S, Levin AA, Hodges MR (2013) Treatment of HCV infection by targeting MicroRNA. N Engl J Med 368(18):1685–1694. https://doi.org/10.1056/nejmoa1209026
Jeong SM, Hwang S, Seong RH (2016) Transferrin receptor regulates pancreatic cancer growth by modulating mitochondrial respiration and ROS generation. Biochem Biophys Res Commun 471(3):373–379. https://doi.org/10.1016/j.bbrc.2016.02.023
Kaur S, Kumar S, Momi N, Sasson AR, Batra SK (2013) Mucins in pancreatic cancer and its microenvironment. Nat Rev Gastroenterol Hepatol 10(10):607–620. https://doi.org/10.1038/nrgastro.2013.120
Kim B, Lee C, Lee ES, Shin BS, Youn YS (2016) Paclitaxel and curcumin co-bound albumin nanoparticles having antitumor potential to pancreatic cancer. Asian Journal of Pharmaceutical Sciences 11(6):708–714. https://doi.org/10.1016/j.ajps.2016.05.005
Klein AP (2012) Identifying people at a high risk of developing pancreatic cancer. Nat Rev Cancer 13(1):66–74. https://doi.org/10.1038/nrc3420
Kunnumakkara AB, Guha S, Krishnan S, Diagaradjane P, Gelovani J, Aggarwal BB (2007) Curcumin potentiates antitumor activity of gemcitabine in an Orthotopic model of pancreatic cancer through suppression of proliferation, angiogenesis, and inhibition of nuclear factor-κB–regulated gene products. Cancer Res 67(8):3853–3861. https://doi.org/10.1158/0008-5472.can-06-4257
Lee GY, Qian WP, Wang L, Wang YA, Staley CA, Satpathy M, Nie S, Mao H, Yang L (2013) Theranostic nanoparticles with controlled release of gemcitabine for targeted therapy and MRI of pancreatic cancer. ACS Nano 7(3):2078–2089. https://doi.org/10.1021/nn3043463
Li J, Liu F, Gupta S, Li C (2016) Interventional Nanotheranostics of pancreatic ductal adenocarcinoma. Theranostics 6(9):1393–1402. https://doi.org/10.7150/thno.15122
Li Y, Sarkar FH (2016) MicroRNA targeted therapeutic approach for pancreatic cancer. Int J Biol Sci 12(3):326–337. https://doi.org/10.7150/ijbs.15017
Li J, Wientjes MG, Au JLS (2010) Pancreatic cancer: pathobiology, treatment options, and drug delivery. AAPS J 12(2):223–232. https://doi.org/10.1208/s12248-010-9181-5
Ling H, Fabbri M, Calin GA (2013) MicroRNAs and other non-coding RNAs as targets for anticancer drug development. Nat Rev Drug Discov 12(11):847–865. https://doi.org/10.1038/nrd4140
Lo JT, Chen BH, Lee TM, Han J, Li JL (2010) Self-emulsifying O/W formulations of paclitaxel prepared from mixed nonionic surfactants. J Pharm Sci 99(5):2320–2332. https://doi.org/10.1002/jps.21993
Longo C, Patanarut A, George T, Bishop B, Zhou W, Fredolini C, Ross MM, Espina V, Pellacani G, Petricoin EF, Liotta LA, Luchini A (2009) Core-Shell hydrogel particles harvest, concentrate and preserve labile low abundance biomarkers. PLoS One 4(3):e4763. https://doi.org/10.1371/journal.pone.0004763
Luchini A, Geho DH, Bishop B, Tran D, Xia C, Dufour RL, Jones CD, Espina V, Patanarut A, Zhou W, Ross MM, Tessitore A, Petricoin EF, Liotta LA (2007) Smart hydrogel particles: biomarker harvesting: one-step affinity purification, size exclusion, and protection against degradation. Nano Lett 8(1):350–361. https://doi.org/10.1021/nl072174l
Luo Y, Li Y, Li J, Fu C, Yu X, Wu L (2019) Hyaluronic acid-mediated multifunctional iron oxide-based MRI nanoprobes for dynamic monitoring of pancreatic cancer. RSC Adv 9(19):10486–10493. https://doi.org/10.1039/c9ra00730j
Macgregor-Das AM, Iacobuzio-Donahue CA (2012) Molecular pathways in pancreatic carcinogenesis. J Surg Oncol 107(1):8–14. https://doi.org/10.1002/jso.23213
Maitra A, Hruban RH (2008) Pancreatic cancer. Annual Review of Pathology: Mechanisms of Disease 3(1):157–188. https://doi.org/10.1146/annurev.pathmechdis.3.121806.154305
Martin L, Li X, Kleiber B, Ellison E, Bloomston M, Zalupski M, Bekaii-Saab T (2012) VEGF remains an interesting target in advanced pancreas cancer (APCA): results of a multi-institutional phase II study of bevacizumab, gemcitabine, and infusional 5-fluorouracil in patients with APCA. Ann Oncol 23(11):2812–2820. https://doi.org/10.1093/annonc/mds134
Mattheolabakis G, Milane L, Singh A, Amiji MM (2015) Hyaluronic acid targeting of CD44 for cancer therapy: from receptor biology to nanomedicine. J Drug Target 23(7–8):605–618. https://doi.org/10.3109/1061186x.2015.1052072
McDermed JE, Sanders R, Fait S, Klem RE, Sarno MJ, Adams TH, Diamandis EP (2012) Nucleic acid detection immunoassay for prostate-specific antigen based on Immuno-PCR methodology. Clin Chem 58(4):732–740. https://doi.org/10.1373/clinchem.2011.170290
Murphy EA, Majeti BK, Barnes LA, Makale M, Weis SM, Lutu-Fuga K, Wrasidlo W, Cheresh DA (2008) Nanoparticle-mediated drug delivery to tumor vasculature suppresses metastasis. Proc Natl Acad Sci 105(27):9343–9348. https://doi.org/10.1073/pnas.0803728105
Neoptolemos JP, Stocken DD, Bassi C, Ghaneh P, Cunningham D, Goldstein D, Padbury R, Moore MJ, Gallinger S, Mariette C, Wente MN, Izbicki JR, Friess H, Lerch MM, Dervenis C, Oláh A, Butturini G, Doi R, Lind PA et al (2010) Adjuvant chemotherapy with fluorouracil plus Folinic acid vs gemcitabine following pancreatic cancer resection. JAMA 304(10):1073. https://doi.org/10.1001/jama.2010.1275
Neoptolemos JP, Stocken DD, Friess H, Bassi C, Dunn JA, Hickey H, Beger H, Fernandez-Cruz L, Dervenis C, Lacaine F, Falconi M, Pederzoli P, Pap A, Spooner D, Kerr DJ, Büchler MW (2004) A randomized trial of Chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 350(12):1200–1210. https://doi.org/10.1056/nejmoa032295
Niemeyer CM, Adler M, Wacker R (2005) Immuno-PCR: high sensitivity detection of proteins by nucleic acid amplification. Trends Biotechnol 23(4):208–216. https://doi.org/10.1016/j.tibtech.2005.02.006
Nigam P, Waghmode S, Louis M, Wangnoo S, Chavan P, Sarkar D (2014) Graphene quantum dots conjugated albumin nanoparticles for targeted drug delivery and imaging of pancreatic cancer. J Mater Chem B 2(21):3190–3195. https://doi.org/10.1039/c4tb00015c
Ohno SI, Takanashi M, Sudo K, Ueda S, Ishikawa A, Matsuyama N, Fujita K, Mizutani T, Ohgi T, Ochiya T, Gotoh N, Kuroda M (2013) Systemically injected exosomes targeted to EGFR deliver antitumor MicroRNA to breast cancer cells. Mol Ther 21(1):185–191. https://doi.org/10.1038/mt.2012.180
Olive KP, Jacobetz MA, Davidson CJ, Gopinathan A, McIntyre D, Honess D, Madhu B, Goldgraben MA, Caldwell ME, Allard D, Frese KK, DeNicola G, Feig C, Combs C, Winter SP, Ireland-Zecchini H, Reichelt S, Howat WJ, Chang A et al (2009) Inhibition of hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 324(5933):1457–1461. https://doi.org/10.1126/science.1171362
Pai P, Rachagani S, Are C, Batra S (2013) Prospects of miRNA-based therapy for pancreatic cancer. Curr Drug Targets 14(10):1101–1109. https://doi.org/10.2174/13894501113149990181
Patra CR, Bhattacharya R, Wang E, Katarya A, Lau JS, Dutta S, Muders M, Wang S, Buhrow SA, Safgren SL, Yaszemski MJ, Reid JM, Ames MM, Mukherjee P, Mukhopadhyay D (2008) Targeted delivery of gemcitabine to pancreatic adenocarcinoma using Cetuximab as a targeting agent. Cancer Res 68(6):1970–1978. https://doi.org/10.1158/0008-5472.can-07-6102
Philip PA, Benedetti J, Corless CL, Wong R, O’Reilly EM, Flynn PJ, Rowland KM, Atkins JN, Mirtsching BC, Rivkin SE, Khorana AA, Goldman B, Fenoglio-Preiser CM, Abbruzzese JL, Blanke CD (2010) Phase III study comparing gemcitabine plus Cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: southwest oncology group–directed intergroup trial S 0205. J Clin Oncol 28(22):3605–3610. https://doi.org/10.1200/jco.2009.25.7550
Qi B, Crawford AJ, Wojtynek NE, Holmes MB, Souchek JJ, Almeida-Porada G, Ly QP, Cohen SM, Hollingsworth MA, Mohs AM (2018) Indocyanine green loaded hyaluronan-derived nanoparticles for fluorescence-enhanced surgical imaging of pancreatic cancer. Nanomedicine 14(3):769–780. https://doi.org/10.1016/j.nano.2017.12.015
Redmond KJ, Wolfgang CL, Sugar EA, Ahn J, Nathan H, Laheru D, Edil BH, Choti MA, Pawlik TM, Hruban RH, Cameron JL, Herman JM (2010) Adjuvant Chemoradiation therapy for adenocarcinoma of the distal pancreas. Ann Surg Oncol 17(12):3112–3119. https://doi.org/10.1245/s10434-010-1200-3
Rifai N, Gillette MA, Carr SA (2006) Protein biomarker discovery and validation: the long and uncertain path to clinical utility. Nat Biotechnol 24(8):971–983. https://doi.org/10.1038/nbt1235
Rosenberger I, Strauss A, Dobiasch S, Weis C, Szanyi S, Gil-Iceta L, Alonso E, González Esparza M, Gómez-Vallejo V, Szczupak B, Plaza-García S, Mirzaei S, Israel L, Bianchessi S, Scanziani E, Lellouche JP, Knoll P, Werner J, Felix K et al (2015) Targeted diagnostic magnetic nanoparticles for medical imaging of pancreatic cancer. J Control Release 214:76–84. https://doi.org/10.1016/j.jconrel.2015.07.017
Ryschich E, Huszty G, Knaebel H, Hartel M, Büchler M, Schmidt J (2004) Transferrin receptor is a marker of malignant phenotype in human pancreatic cancer and in neuroendocrine carcinoma of the pancreas. Eur J Cancer 40(9):1418–1422. https://doi.org/10.1016/j.ejca.2004.01.036
Scaros O, Fisler R (2005) Biomarker technology roundup: from discovery to clinical applications, a broad set of tools is required to translate from the lab to the clinic. BioTechniques 38(4S):S30–S32. https://doi.org/10.2144/05384su01
Shamseddine A, Saleh A, Charafeddine M, Seoud M, Mukherji D, Temraz S, Sibai AM (2014) Cancer trends in Lebanon: a review of incidence rates for the period of 2003–2008 and projections until 2018. Popul Health Metrics 12(1). https://doi.org/10.1186/1478-7954-12-4
Siegel R, Ma J, Zou Z, Jemal A (2014) Cancer statistics, 2014. CA Cancer J Clin 64(1):9–29. https://doi.org/10.3322/caac.21208
Sivasankarapillai V, Das SS, Sabir F, Sundaramahalingam M, Colmenares J, Prasannakumar S, Rajan M, Rahdar A, Kyzas G (2021) Progress in natural polymer engineered biomaterials for transdermal drug delivery systems. Materials Today Chemistry 19:100382. https://doi.org/10.1016/j.mtchem.2020.100382
Tamburro D, Fredolini C, Espina V, Douglas TA, Ranganathan A, Ilag L, Zhou W, Russo P, Espina BH, Muto G, Petricoin EF, Liotta LA, Luchini A (2011) Multifunctional core–shell nanoparticles: discovery of previously invisible biomarkers. J Am Chem Soc 133(47):19178–19188. https://doi.org/10.1021/ja207515j
Thapa RK, Ku SK, Choi HG, Yong CS, Byeon JH, Kim JO (2018) Vibrating droplet generation to assemble zwitterion-coated gold-graphene oxide stealth nanovesicles for effective pancreatic cancer chemo-phototherapy. Nanoscale 10(4):1742–1749. https://doi.org/10.1039/c7nr07603g
Trabulo S, Aires A, Aicher A, Heeschen C, Cortajarena AL (2017) Multifunctionalized iron oxide nanoparticles for selective targeting of pancreatic cancer cells. Biochim Biophys Acta Gen Subj 1861(6):1597–1605. https://doi.org/10.1016/j.bbagen.2017.01.035
Vincent A, Herman J, Schulick R, Hruban RH, Goggins M (2011) Pancreatic cancer. Lancet 378(9791):607–620. https://doi.org/10.1016/s0140-6736(10)62307-0
Wang L, An Y, Yuan C, Zhang H, Liang C, Ding F, Gao Q, Zhang D (2015) GEM-loaded magnetic albumin nanospheres modified with cetuximab for simultaneous targeting, magnetic resonance imaging, and double-targeted thermochemotherapy of pancreatic cancer cells. Int J Nanomedicine 2507. https://doi.org/10.2147/ijn.s77642
Wu Y, Crawford M, Mao Y, Lee RJ, Davis IC, Elton TS, Lee LJ, Nana-Sinkam SP (2013) Therapeutic delivery of MicroRNA-29b by cationic Lipoplexes for lung cancer. Molecular Therapy–Nucleic Acids 2:e84. https://doi.org/10.1038/mtna.2013.14
Wu L, Qu X (2015) Cancer biomarker detection: recent achievements and challenges. Chem Soc Rev 44(10):2963–2997. https://doi.org/10.1039/c4cs00370e
Yachida S, Iacobuzio-Donahue CA (2009) The pathology and genetics of metastatic pancreatic cancer. Arch Pathol Lab Med 133(3):413–422. https://doi.org/10.5858/133.3.413
Yallapu MM, Ebeling MC, Khan S, Sundram V, Chauhan N, Gupta BK, Puumala SE, Jaggi M, Chauhan SC (2013) Novel curcumin-loaded magnetic nanoparticles for pancreatic cancer treatment. Mol Cancer Ther 12(8):1471–1480. https://doi.org/10.1158/1535-7163.mct-12-1227
Zhang X, Lu J, Huang Y, Zhao W, Chen Y, Li J, Gao X, Venkataramanan R, Sun M, Stolz DB, Zhang L, Li S (2013) PEG-Farnesylthiosalicylate conjugate as a Nanomicellar carrier for delivery of paclitaxel. Bioconjug Chem 24(3):464–472. https://doi.org/10.1021/bc300608h
Zheng T, Finn C, Parrett CJ, Dhume K, Hwang JH, Sidhom D, Strutt TM, Li Sip YY, McKinstry KK, Huo Q (2017) A rapid blood test to determine the active status and duration of acute viral infection. ACS Infectious Diseases 3(11):866–873. https://doi.org/10.1021/acsinfecdis.7b00137
Zheng T, Pierre-Pierre N, Yan X, Huo Q, Almodovar AJ, Valerio F, Rivera-Ramirez I, Griffith E, Decker DD, Chen S, Zhu N (2015) Gold nanoparticle-enabled blood test for early stage cancer detection and risk assessment. ACS Appl Mater Interfaces 7(12):6819–6827. https://doi.org/10.1021/acsami.5b00371
Zhou H, Qian W, Uckun FM, Wang L, Wang YA, Chen H, Kooby D, Yu Q, Lipowska M, Staley CA, Mao H, Yang L (2015) IGF1 receptor targeted Theranostic nanoparticles for targeted and image-guided therapy of pancreatic cancer. ACS Nano 9(8):7976–7991. https://doi.org/10.1021/acsnano.5b01288
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2022 The Author(s), under exclusive license to Springer Nature Singapore Pte Ltd.
About this chapter
Cite this chapter
Das, S.S., Dubey, A.K., Singh, N., Verma, P.R.P., Singh, S.K., Singh, S.K. (2022). Pancreatic Cancer Treatment by Using Theragnostic Nanoparticles. In: Rahman, M., H Almalki, W., Alrobaian, M., Beg, S., Alharbi, K.S. (eds) Hormone Related Cancer Mechanistic and Nanomedicines. Springer, Singapore. https://doi.org/10.1007/978-981-19-5558-7_8
Download citation
DOI: https://doi.org/10.1007/978-981-19-5558-7_8
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-19-5557-0
Online ISBN: 978-981-19-5558-7
eBook Packages: MedicineMedicine (R0)